The story of Viagra, formerly marketed by copyright, presents a fascinating case study for investors considering the pharmaceutical landscape . While its initial success and creation of vast in earnings , the exclusivity expiration has opened the floodgates for generic medications, greatly eroding income opportunities. This transition raises doubts